A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

[1] Moreno-Aspitia A(2009)Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends Clin Ther 31 1619-1640

[2] Perez EA(2002)Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor Clin Cancer Res 8 1051-1056

[3] Kornek GV(2004)Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study Oncology 67 250-256

[4] Haider K(2007)Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399-3406

[5] Kwasny W(2000)A unified definition of clinical anthracycline resistance breast cancer Br J Cancer 82 529-534

[6] Raderer M(2006)Gemcitabine and taxanes in metastatic breast cancer Ann Oncol 17 v173-v176

[7] Schull B(2004)Rationale for the use of gemcitabine in breast cancer (review) Int J Oncol 24 389-398

[8] Payrits T(2001)Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond Oncologist 6 133-146

[9] Depisch D(2010)Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG) Breast Cancer Res Treat 119 169-176

[10] Kovats E(2004)Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer Ann Oncol 15 95-99

[1] Moreno-Aspitia A(2009)Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends Clin Ther 31 1619-1640

[2] Perez EA(2002)Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor Clin Cancer Res 8 1051-1056

[3] Kornek GV(2004)Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study Oncology 67 250-256

[4] Haider K(2007)Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399-3406

[5] Kwasny W(2000)A unified definition of clinical anthracycline resistance breast cancer Br J Cancer 82 529-534

[6] Raderer M(2006)Gemcitabine and taxanes in metastatic breast cancer Ann Oncol 17 v173-v176

[7] Schull B(2004)Rationale for the use of gemcitabine in breast cancer (review) Int J Oncol 24 389-398

[8] Payrits T(2001)Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond Oncologist 6 133-146

[9] Depisch D(2010)Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG) Breast Cancer Res Treat 119 169-176

[10] Kovats E(2004)Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer Ann Oncol 15 95-99